<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00153049</url>
  </required_header>
  <id_info>
    <org_study_id>502.439</org_study_id>
    <nct_id>NCT00153049</nct_id>
  </id_info>
  <brief_title>3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo-Controlled, 3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      1. To investigate the dose response of the combination therapy, Telmisartan and
           Hydrochlorothiazide for the Japanese patients with Essential Hypertension.

        2. To compare this dose response with that in the US study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an 8-week multicentre, randomised, double-blind, double-dummy, placebo-controlled,
      parallel group study utilizing all cells of a 3 x 3 factorial design. Following Screening
      examinations and a 4-week Placebo Run-In Period, 540 patients will be randomized to receive
      once-daily monotherapy with either telmisartan (MICARDIS), hydrochlorothiazide, placebo, or
      combination therapy with telmisartan and hydrochlorothiazide for 8 weeks (Treatment Period).

      This study includes nine cells, placebo, telmisartan (TEL) 40 mg, TEL 80 mg,
      hydrochlorothiazide (HCTZ) 6.25 mg, HCTZ 12.5 mg, TEL 40 mg/HCTZ 6.25 mg, TEL 40 mg/HCTZ 12.5
      mg, TEL 80 mg/HCTZ 6.25 mg, and TEL 80 mg/HCTZ 12.5 mg.

      Study Hypothesis:

      The hypothesis is that the dose response model for the Japanese patient with essential
      hypertension which is constructed for the change of the supine diastolic blood pressure from
      the baseline value to end of treatment with the multiple regression analysis, is similar to
      that in the US study 502.204.

      Comparison(s):

      The primary efficacy parameter will be the change from baseline in supine diastolic blood
      pressure at trough (24 hours post-dose) at the last visit during the Double-Blind Period.

      The dose response surface model will be constructed. The graphs of dose response surface will
      be generated based on the final model. The model in this study will compare with that in US
      study from the perspective of including the same terms in the model.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date>June 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in supine diastolic blood pressure (DBP) at trough (24 hours post-dose)</measure>
    <time_frame>after 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in supine systolic blood pressure (SBP) at trough (24 hours post-dose)</measure>
    <time_frame>after 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sitting systolic and diastolic blood pressure at trough (24 hours post-dose)</measure>
    <time_frame>after 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DBP control rate</measure>
    <time_frame>after 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DBP response rate</measure>
    <time_frame>after 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP response rate</measure>
    <time_frame>after 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>up to 8 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">583</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan + Hydrochlorothiazide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Essential hypertensive patients who meet the following criteria:

               -  Mean supine DBP &gt;= 95 and &lt;= 114 mm Hg at each of Visits 2 and 3.

               -  Mean supine DBP must not vary by more than 10 mm Hg between Visit 2 and Visit 3.

               -  Mean supine systolic blood pressure (SBP) must be &gt;= 140 and &lt;= 200 mm Hg at
                  Visit 3.

             (The mean DBP and SBP values are calculated as the mean of the three supine
             measurements taken two minutes apart.)

          2. Male or female.

          3. Age &gt;= 20 and Age &lt;= 80 years.

          4. Outpatient.

          5. Able to stop current antihypertensive therapy without risk to the patient.

          6. Ability to provide written Informed Consent in accordance with ?Good Clinical Practice
             (GCP)? (MHW Ordinance No. 28, as of Mar. 27, 1997) and the local legislation.

        Exclusion Criteria:

          1. Known or suspected secondary hypertension (renovascular hypertension, primary
             aldosteronism, melanocytoma, etc.).

          2. Mean supine DBP &gt; 114 mmHg and/or mean supine SBP &gt; 200 mmHg during any visit of the
             placebo run-in period.

          3. Sustained ventricular tachycardia or other clinically relevant cardiac arrhythmias
             (atrioventricular conduction disturbance (grade II - III), atrial fibrillation etc.).

          4. NYHA functional class heart failure III-IV.

          5. Myocardial infarction or cardiac surgery within 6 months of signing the informed
             consent form.

          6. Coronary artery bypass surgery or percutaneous transluminal coronary angioplasty
             (PTCA) within 3 months of signing the informed consent form.

          7. Unstable angina within 3 months of signing the informed consent form.

          8. Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant
             stenosis of aortic or mitral valve.

          9. Stroke or transient ischemic attack within 6 months of signing the informed consent
             form.

         10. History of sudden exacerbation of renal function with AT1 receptor antagonists or ACE
             inhibitors; post-renal transplant.

         11. Patients who have previously experienced characteristic symptoms of angioedema (such
             as facial, tongue, pharyngeal, laryngeal swelling with dyspnea) during treatment with
             AT1 receptor antagonists or ACE inhibitors.

         12. Known hypersensitivity to any component of the formulation, or a known
             hypersensitivity to sulfonamides or sulphonamide-derived drugs (e.g. thiazides).

         13. Hepatic and/or renal dysfunction as defined by the following laboratory parameters:

               -  SGPT(ALT) or SGOT(AST) &gt;= 2 times the upper limit of normal at screening (Visit
                  1).

               -  Patients who have markedly poor bile secretion by the following laboratory
                  parameters: Patients whose direct bilirubin &gt;= 2.0 mg/dL at screening (Visit 1).

               -  Serum creatinine &gt;= 2.1 mg/dL at screening (Visit 1).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim Study Coordinator</last_name>
    <role>Study Chair</role>
    <affiliation>Nippon Boehringer Ingelheim Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Annaka, Gunma</city>
        <zip>379-0016</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Asahi,Chiba</city>
        <zip>289-2151</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <zip>814-0163</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <zip>819-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ichinomiya, Aichi</city>
        <zip>491-0851</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Iida,Nagano</city>
        <zip>395-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Inzai, Chiba</city>
        <zip>270-1347</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Isesaki, Gunma</city>
        <zip>372-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kako-gun, Hyogo</city>
        <zip>675-1112</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kasuya-gun,Fukuoka</city>
        <zip>811-2311</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Katsushika-ku,Tokyo</city>
        <zip>124-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kobe, Hyogo</city>
        <zip>651-0072</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koshigaya, Saitama</city>
        <zip>343-0856</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mono-gun, Miyagi</city>
        <zip>981-0503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <zip>530-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <zip>550-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sendai, Miyagi</city>
        <zip>980-8660</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Setagun, Gunma</city>
        <zip>377-0061</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinjyuku, Tokyo</city>
        <zip>160-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shiroishi, Miyagi</city>
        <zip>989-0228</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shiroishi, Miyagi</city>
        <zip>989-0231</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suita, Osaka</city>
        <zip>565-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Takasaki, Gunma</city>
        <zip>370-0811</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taya-gun, Gunma</city>
        <zip>370-2132</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>November 7, 2013</last_update_submitted>
  <last_update_submitted_qc>November 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2013</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Telmisartan, hydrochlorothiazide drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

